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Transcatheter aortic valve replacement (TAVR) has
transformed the treatment of aortic stenosis in high-risk
older adults in Europe and has begun to do so in the United
States. Recent Food and Drug Administration approval of
the Edwards Lifesciences SAPIEN Transcatheter Heart
Valve (Irvine, Calif) in inoperable and high-risk patients
led to enthusiasm for widespread implementation of this
technology. Experts have highlighted the central role of
the multidisciplinary heart team in implementing a success-
ful TAVR program.1 Other experts, such as Joseph Bavaria,
have suggested that access to TAVR should be restricted to
high-volume surgical aortic valve replacement centers. In
our opinion, access to TAVR should not be limited to
high-volume surgical centers for the following reasons.
First, high surgical volume does not ensure good outcomes
in complex interventional procedures. Second, centers with
low or no surgical volume can have excellent interventional
results. Third, new multidisciplinary heart teams have
achieved excellent results in part because of the transmis-
sion of accumulated knowledge from experienced centers.
Finally, in the absence of evidence suggesting that high-
volume surgical centers produce superior TAVR results,
therapeutic options for patients should not be limited.
HIGH SURGICALVOLUME DOES NOT ENSURE
GOOD INTERVENTIONAL OUTCOMES
The Synergy between Percutaneous Coronary Angio-
plasty with Taxus and Cardiac Surgery (SYNTAX) trial2
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nary artery bypass surgery or a Taxus stent (Boston Scien-
tific Corporation, Natick, Mass) implantation. Analysis of
rates of major adverse cardiac events by site showed that
there was no relationship between volume and outcomes
for both the Taxus stent and coronary bypass arm of the
trial. This indicates that high volume, surgical or percutane-
ous, does not guarantee excellent outcomes and therefore
volume alone should not be treated as a sufficient marker
of high-quality care.CENTERS WITH LOW OR NO SURGICAL
VOLUME CAN HAVE EXCELLENT
INTERVENTIONAL RESULTS
Recent data from the Cardiovascular Patient Outcomes
Research Team–Elective Angioplasty Study (CPORT-E)
trial confirmed that surgical backup is not necessary for ex-
cellent interventional outcomes.3 In the CPORT-E study,
approximately 1900 patients were randomized to percuta-
neous coronary intervention with surgery on site versus
no surgery onsite. The overall 6-week and 9-month adverse
cardiac event rates were low and there were no significant
differences between the sites with and without surgical
backup. These findings underscore the belief that high sur-
gical volume is not essential for excellent interventional
cardiology results.GROUP LEARNING CAN ATTENUATE THE
LEARNING CURVE
Data from the Columbia HeartSource experience have
shown that high-volume centers of excellence can transmit
expertise to outlying centers. This can be achieved through
targeted physician recruitment, a focus on continuous qual-
ity improvement through regular oversight and peer review,
and formal and informal didactics. Most importantly, expert
consultation is available to all participating sites at all times,
including nights and weekends. The use of this approach to
transmit knowledge across sites has enabled low-volume
sites to achieve cardiac surgical risk-adjusted outcomes
that are comparable with high-volumes affiliates.4
This group-learning phenomena has been replicated on
a larger scale in the transcatheter arena in Europe and in
the United States. In the European Edwards SAPIENAortic
Bioprosthesis European Outcome (SOURCE) Registry, the
early (January 2008 to January 2009; n ¼ 575) and later
(February 2009 to January 2010; n ¼ 819) transapical
TAVR results were compared. Despite comparable baselinegery c June 2013
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good as outcomes in the later group. Specifically, there
were no differences in 30-day rates of death, stroke, bleed-
ing, or vascular complications.5 The absence of a demonstra-
ble learning curve is a result of shared knowledge across
sites, enabling each site to rapidly integrate the collective
experience to achieve results comparable with more experi-
enced sites. The early US TAVR experience also showed
that group learning can attenuate the learning curve. Dewey
and colleagues (STS presentation; January, 2012) analyzed
the randomized and nonrandomized continued-access trans-
femoral TAVR Placement of Aortic Transcatheter Valve
(PARTNER) trial experience and showed the following:
(1) 30-day and 1-year mortality rates among the TAVR
subjects were not different when high-enrolling sites were
compared with low-enrolling sites, and (2) the 30-day and
1-year mortality rates were similar for the first set of 20,
the second set of 20, and the third set of 20 valve implanta-
tions at each site (PARTNER Executive Committee presen-
tation; April, 2012). This suggests that early lessons learned
were integrated rapidly into the group experience and
through formal and informal educational initiatives and
hands-on proctoring, excellent results were achieved in
low-volume sites and among the first cases at new sites.
Finally, although we applaud the careful assimilation of
TAVR technology to clinical care to ensure optimal out-
comes for the highest-risk patients, restricting this kind of
therapy to centers with high surgical aortic valve replace-
ment volume is unprecedented in the surgical community.
Bolling and colleagues6 highlighted that most mitral valve
surgery occurs at low-volume sites, despite the increased
likelihood of successful mitral valve repair at high-
volume centers. Furthermore, Dewey and colleagues7The Journal of Thoracic and Carshowed that the discordance between observed and ex-
pected outcomes after aortic valve replacement decreases
as surgical volume increases. However, according to data
from the Society of Thoracic Surgery database, the median
number of sole aortic valve replacements per center is 20
per year, and per cardiac surgeon is 8 per year (Society of
Thoracic Surgery database; 2010). Despite evidence of
better outcomes at high-volume surgical centers, heart valve
surgery is not restricted to high-volume centers. In TAVR,
in which the available evidence suggests that an excellent
heart team with the support of national experts and regional
centers can achieve excellent results despite low volume,
there is no rationale to restrict the availability of this trans-
formative technology to patients cared for at high-volume
surgical centers.References
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